Diversified Sri Lankan conglomerate Hemas Holdings PLC reported a 17.6% rise in net profit to Rs. 3.03 billion for the quarter ended 31 March 2026, according to its interim financial report.
Consolidated revenue for the three months grew 3.9% to Rs. 31.54 billion, supported by the consumer and healthcare sectors despite global commodity price pressures and a mild rupee depreciation. Gross profit jumped 16.9% to Rs. 10.89 billion, with margins expanding to 34.5%, while operating profit rose 13.5% to Rs. 4.34 billion. Earnings came in at Rs. 1.01 per share, up from Rs. 0.90 a year earlier, as net finance costs fell 25.9% to Rs. 172 million.
Healthcare was the largest contributor, with revenue up 3.4% to Rs. 20.41 billion and sector earnings up 9.3% to Rs. 1.69 billion. Hemas Pharmaceuticals retained market leadership and its manufacturing arm, Morison, recorded 18.6% volume growth. Consumer brand revenue rose 4.5% to Rs. 10.55 billion, with Sri Lankan Home and Personal Care volumes up 16.6% and the Bangladesh operation growing revenue 11%.
The mobility sector’s revenue rose 15.6% to Rs. 563 million, but earnings fell 15% to Rs. 227 million as the Middle East crisis hit aviation passenger volumes; the maritime arm (Evergreen) saw TEU volume growth of 44%. The group said it is entering its next financial year focused on a “FY30 Long Range Plan” involving about US$ 100 million in investment over four years. The board approved a final dividend of Rs. 0.75 per share following a 1:5 share split, and the stock closed up 4.19% at Rs. 32.30.
The results add to a strong corporate earnings season that has included record quarters at Dialog Axiata, the Bank of Ceylon and Commercial Bank.
